Data / Form D filings / Xilis, Inc.
Xilis, Inc.: Form D filings
Xilis, Inc., a biotechnology company in Durham, NC, filed 5 Form D notices with the SEC between 2019 and 2025. The latest, on April 25, 2025, reports $19.4 million sold of a $19.4 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 31 ALEXANDRIA WAY, Durham, NC, 27713
- Phone
- (984) 377-6738
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1796056
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 25, 2025 | New notice | $19,405,205 | $19,405,205 | 9 | Apr 10, 2025 | sec.gov | |
| Jul 14, 2022 | New notice | $16,514,618 | $16,514,618 | 14 | Jun 1, 2022 | sec.gov | |
| Jul 9, 2021 | New notice | $70,000,006 | $70,000,006 | 17 | Jun 24, 2021 | sec.gov | |
| May 21, 2020 | Amendment | $4,849,998 | $4,849,998 | 8 | Nov 19, 2019 | sec.gov | |
| Dec 6, 2019 | New notice | $3,000,000 | $2,999,999 | $1 | 6 | Nov 19, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Alaa Roy Halawa | Director | |
| John Roy de Koning | Director | |
| William Roy Smythe | Executive Officer, Director |
Other biotechnology companies in North Carolina that filed recently
- Toggle Bio $200,000 · Oct 6, 2026
- Swift Cardiovascular, Inc. $810,000 · Sep 24, 2026
- Aclarity Genomics, Inc. $4.6 million · Sep 2, 2026
- Aer Therapeutics, Inc. $3 million · Aug 19, 2026
Every Form D from the week of Apr 21, 2025 · All recent filings in North Carolina · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Xilis, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.